Related Experiment Video
Updated: Apr 11, 2026

Polygraphic Recording Procedure for Measuring Sleep in Mice
Published on: January 25, 2016
Optimization of Melatonin Dissolution from Extended Release Matrices Using Artificial Neural Networking
D Martarelli, L Casettari1, K S Shalaby
1Department of Biomolecular Sciences, School of Pharmacy, University of Urbino, Piazza Rinascimento n°6, 61029, Urbino (PU), Italy. luca.casettari@uniurb.it.
Background:
Efficacy of melatonin in treating sleep disorders has been demonstrated in numerous studies. Being with short half-life, melatonin needs to be formulated in extended-release tablets to prevent the fast drop of its plasma concentration. However, an attempt to mimic melatonin natural plasma levels during night time is challenging.
Methods:
In this work, Artificial Neural Networks (ANNs) were used to optimize melatonin release from hydrophilic polymer matrices. Twenty-seven different tablet formulations with different amounts of hydroxypropyl methylcellulose, xanthan gum and Carbopol®974P NF were prepared and subjected to drug release studies. Using dissolution test data as inputs for ANN designed by Visual Basic programming language, the ideal number of neurons in the hidden layer was determined trial and error methodology to guarantee the best performance of constructed ANN.
Results:
Results showed that the ANN with nine neurons in the hidden layer had the best results. ANN was examined to check its predictability and then used to determine the best formula that can mimic the release of melatonin from a marketed brand using similarity fit factor.
Conclusion:
This work shows the possibility of using ANN to optimize the composition of prolonged-release melatonin tablets having dissolution profile desired.
Related Concept Videos
Management of Insomnia
Factors Affecting Dissolution: Particle Size and Effective Surface Area
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Modified-Release Drug Delivery Systems: Classification

